<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Yonsei Med J</journal-id>
      <journal-id journal-id-type="publisher-id">YMJ</journal-id>
      <journal-title-group>
        <journal-title>Yonsei Medical Journal</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0513-5796</issn>
      <issn pub-type="epub">1976-2437</issn>
      <publisher>
        <publisher-name>Yonsei University College of Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17066519</article-id>
      <article-id pub-id-type="pmc">2687761</article-id>
      <article-id pub-id-type="doi">10.3349/ymj.2006.47.5.737</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Scleroderma-like Manifestation in a Patient with Primary Systemic Amyloidosis: Response to High-dose Intravenous Immunoglobulin and Plasma Exchange</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cho</surname>
            <given-names>Sung Bin</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Jun Su</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Hyun Ok</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Chung</surname>
            <given-names>Kee Yang</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.</aff>
      <author-notes>
        <corresp>Reprint address: requests to Dr. Kee Yang Chung, Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea, Tel: 82-2-2228-2080, Fax: 82-2-393-9157, <email>kychung@yumc.yonsei.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>31</day>
        <month>10</month>
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>10</month>
        <year>2006</year>
      </pub-date>
      <volume>47</volume>
      <issue>5</issue>
      <fpage>737</fpage>
      <lpage>740</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>1</month>
          <year>2005</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>6</month>
          <year>2005</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2006 The Yonsei University College of Medicine</copyright-statement>
        <copyright-year>2006</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A 54-year-old Korean male with scleroderma-like manifestation of primary systemic amyloidosis presented with firm cutaneous induration of face and distal extremities, subcutaneous induration of the trunk and proximal extremities, limited range of motion in all joints, hoarseness, and dysphagia. Monthly high-dose intravenous immunoglobulin (hdIVIg) was given (three treatments, each time administering 0.4 g/kg per day for five days), and both signs and symptoms began to improve. However, the quantitative analyses of serum protein did not improve. Therapeutic plasma exchange (TPE) was performed monthly to clear the elevated serum immunoglobulin, and after several treatments, their levels normalized and symptoms were maintained in the improved state for more than two years. To summarize, hdIVIg and TPE combination therapy may be used as a safe first-line treatment for patients with primary systemic amyloidosis presenting with symptomatic monoclonal gammopathy.</p>
      </abstract>
      <kwd-group>
        <kwd>Amyloidosis</kwd>
        <kwd>plasma exchange</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Amyloidosis refers to a heterogeneous group of disorders characterized by extracellular deposition of proteinaceous fibrillar materials (termed amyloid) in various tissues and organs.<xref ref-type="bibr" rid="B1">1</xref> It can be divided into two major forms: amyloid light chain (AL) amyloidosis and amyloid A amyloidosis.<xref ref-type="bibr" rid="B2">2</xref> Clinical skin involvement occurs in approximately 25% of patients with AL amyloidosis,<xref ref-type="bibr" rid="B3">3</xref> and common manifestations include petechiae, purpura, ecchymoses, papules, nodules, plaques, and tumefactive lesions; a scleroderma-like manifestation is rarely seen.<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref></p>
      <p>Therapeutic plasma exchange (TPE) has been proven to be an effective treatment in patients showing monoclonal gammopathy.<xref ref-type="bibr" rid="B6">6</xref> We applied TPE to treat an AL amyloidosis patient with scleroderma-like manifestations because the amyloids in AL amyloidosis are derived from the monoclonal immunoglobulin light chains produced by plasma cells.</p>
    </sec>
    <sec sec-type="cases">
      <title>CASE REPORT</title>
      <p>A 54-year-old Korean male was first referred to our department on October 4, 2001, with a history of hoarseness, difficulty in swallowing, and progressive generalized hardening of the body that had progressed over the past two years. The skin on his face and distal extremities was indurated, and several brownish and shiny papules were noted on the forehead and perioral area. On the trunk and proximal extremities, the skin was normal in elasticity, but the underlying muscles were indurated, and almost all of the joints were restricted in motion (<xref ref-type="fig" rid="F1">Fig. 1A</xref>, <xref ref-type="table" rid="T1">Table 1</xref>). Quantitative analyses of serum protein revealed concentrations of immunoglobulin G (IgG) of 1,780 mg/dl and kappa (&#x3BA;) light chain of 532 mg/dl (the normal ranges are 700-1,600 mg/dl and 170-370 mg/dl, respectively). Serum immunofixation showed a characteristic pattern of monoclonal IgG gammopathy, particularly of &#x3BA; paraprotein. Laryngoscopic examinations revealed granulomatous materials deposited in the vocal cords, and nerve conduction studies showed polyneuropathy of the sensory nerves. Impaired left ventricular systolic function and thickening of the left ventricular walls with restrictive filling were noted upon echocardiography. There were no remarkable findings in various studies, including a bone marrow aspiration study, abdominal ultrasonography, and esophagography. The skin biopsy specimens showed a deposition of amyloid materials in the dermis, subcutaneous tissues, and in the connective tissue septae of the skeletal muscle by Congo-red stain (<xref ref-type="fig" rid="F1">Fig. 1C</xref>), and it produced a characteristic apple-green birefringence when viewed under a polarized light source (<xref ref-type="fig" rid="F1">Fig. 1D</xref>).</p>
      <p>After failure to control the symptoms with systemic steroids, colchicine, or cyclophosphamide, monthly high-dose intravenous immunoglobulin (hdIVIg) was infused for three courses of treatment (each time giving 0.4 g/kg/day for five days); the patient noted improvement in subjective symptoms such as tightness of legs and dysphagia, and the range of motion of his joints began to improve as early as three weeks after the first treatment (<xref ref-type="fig" rid="F1">Fig. 1B</xref>, <xref ref-type="table" rid="T1">Table 1</xref>). However, the elevated IgG and &#x3BA; light chain levels did not decrease, despite the symptomatic changes, and the symptoms progressed with the discontinuation of hdIVIg therapy. Although the patient had no apparent renal dysfunction, the concern of potential renal involvement in systemic amyloidosis and the possibility that hdIVIg would enhance that risk made us decide to discontinue further hdIVIg therapy. To clear the excess serum immunoglobulin, which was constantly elevated despite the hdIVIg therapy, monthly TPE was performed, and the normalized serum immunoglobulin levels and the symptoms and signs, including dysphagia, tightness of legs, induration of skin, and the limited range of motion, were maintained in an improved state for more than two years.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Most reports on the treatment of primary and myeloma-associated systemic amyloidosis have been anecdotal, and responses to treatment are difficult to assess because of the poor correlation between amyloid load and organ dysfunction.<xref ref-type="bibr" rid="B7">7</xref> Cytotoxic chemotherapy is the mainstay of treatment, and melphalan, prednisone, colchicine, penicillamine, azathioprine, vincristine, and cyclophosphamide have been used in the treatment of systemic amyloidosis. Cohen et al.<xref ref-type="bibr" rid="B8">8</xref> reported that colchicine was found to improve life expectancy in 53 patients with AL amyloidosis. Erikkson et al.<xref ref-type="bibr" rid="B9">9</xref> proposed the therapeutic implications of &#x3B1;1-antitrypsin. More aggressive chemotherapy, myeloablation, and autologous bone marrow transplantation have been proposed as novel therapeutic approaches.<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref> Immunotoxins directed against the precursors of the amyloidogenic plasma cells are under investigation.<xref ref-type="bibr" rid="B9">9</xref> Conflicting evidence exists concerning vitamin C and vitamin E.<xref ref-type="bibr" rid="B7">7</xref> Merlini et al.<xref ref-type="bibr" rid="B10">10</xref> showed that doxorubicin derivatives play a role in enhancing the resorption of AL amyloid <italic>in vitro</italic> and in murine models.</p>
      <p>HdIVIg has increasingly been used for the treatment of certain dermatoses, such as bullous autoimmune diseases and erythema multiforme.<xref ref-type="bibr" rid="B12">12</xref> Lister et al.<xref ref-type="bibr" rid="B13">13</xref> reported two patients with scleromyxedema who showed a dramatic response to treatment with hdIVIg. Krastev et al.<xref ref-type="bibr" rid="B14">14</xref> reported a case of gastrointestinal amyloidosis showing clinical improvement with hdIVIg treatment, as in our case.</p>
      <p>Although the majority of cases reported to date show an absence of or only slight adverse side-effects with hdIVIg, it is suggested that hdIVIg therapy may enhance the risk of adverse side-effects, and should be carefully considered in patients with pre-existent diseases such as congestive heart failure, immobilization, or renal insufficiency.<xref ref-type="bibr" rid="B15">15</xref> In addition, dysproteinemia due to hdIVIg therapy itself may result in cast nephropathy and renal failure. Although the patient had no apparent renal dysfunction, to avoid potential renal involvement in systemic amyloidosis and other possible risks of hdIVIg, we decided against further hdIVIg therapy. Also, considering that hdIVIg could not effectively reduce the level of serum paraprotein, TPE seemed to be an effective and safe alternative for removing the paraproteins, which is ultimately necessary to prevent disease progression. TPE is regarded as being less effective than hdIVIg therapy for the treatment of amyloidosis. However, it is effective in patients with symptomatic monoclonal gammopathy because it removes the paraproteins very efficiently, particularly in patients who do not respond to drug therapy.<xref ref-type="bibr" rid="B4">4</xref></p>
      <p>In conclusion, hdIVIg and TPE combination therapy may be used as a safe first-line treatment for patients with primary systemic amyloidosis presenting symptomatic monoclonal gammopathy. However, long term follow-up is needed to fully elucidate the effects of combination therapy, and the application of these treatments in a larger group of patients is necessary.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Husby</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Nomenclature and classification of amyloid and amyloidoses</article-title>
          <source>J Intern Med</source>
          <year>1992</year>
          <volume>232</volume>
          <fpage>511</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="pmid">1474353</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Greipp</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Amyloidosis (AL). Clinical and laboratory features in 229 cases</article-title>
          <source>Mayo Clin Proc</source>
          <year>1983</year>
          <volume>58</volume>
          <fpage>665</fpage>
          <lpage>683</lpage>
          <pub-id pub-id-type="pmid">6353084</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Bayrd</surname>
              <given-names>ED</given-names>
            </name>
          </person-group>
          <article-title>Amyloidosis: review of 236 cases</article-title>
          <source>Medicine (Baltimore)</source>
          <year>1975</year>
          <volume>54</volume>
          <fpage>271</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">1152671</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Breathnach</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Freedberg</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Eisen</surname>
              <given-names>AZ</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Austen</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Goldsmith</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
          <article-title>Amyloidosis of the skin</article-title>
          <source>Fitzpatrick's dermatology in general medicine</source>
          <year>1993</year>
          <volume>Vol. 2</volume>
          <edition>6th ed</edition>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>McGraw-Hill Companies</publisher-name>
          <fpage>1428</fpage>
          <lpage>1435</lpage>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>CK</given-names>
            </name>
          </person-group>
          <article-title>Dermatopathologic findings in 20 cases of systemic amyloidosis</article-title>
          <source>Am J Dermatopathol</source>
          <year>1998</year>
          <volume>20</volume>
          <fpage>438</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="pmid">9790101</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drew</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Plasmapheresis in the dysproteinemias</article-title>
          <source>Ther Apher</source>
          <year>2002</year>
          <volume>6</volume>
          <fpage>45</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">11886576</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gertz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Amyloidosis: prognosis and treatment</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>1994</year>
          <volume>24</volume>
          <fpage>124</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="pmid">7839154</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cohen</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Rubinow</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Skinner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Libbey</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973)</article-title>
          <source>Am J Med</source>
          <year>1987</year>
          <volume>82</volume>
          <fpage>1182</fpage>
          <lpage>1190</lpage>
          <pub-id pub-id-type="pmid">3605135</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eriksson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Janciauskiene</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Merlini</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils</article-title>
          <source>J Intern Med</source>
          <year>1995</year>
          <volume>237</volume>
          <fpage>143</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="pmid">7852916</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Merlini</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Treatment of primary amyloidosis</article-title>
          <source>Semin Hematol</source>
          <year>1995</year>
          <volume>32</volume>
          <fpage>60</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="pmid">7878479</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Comenzo</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Gertz</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Autologous stem cell transplantation for primary systemic amyloidosis</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>4276</fpage>
          <lpage>4282</lpage>
          <pub-id pub-id-type="pmid">12036853</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schofield</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Tatnall</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Leigh</surname>
              <given-names>IM</given-names>
            </name>
          </person-group>
          <article-title>Recurrent erythema multiforme: clinical features and treatment in a large series of patients</article-title>
          <source>Br J Dermatol</source>
          <year>1993</year>
          <volume>128</volume>
          <fpage>542</fpage>
          <lpage>545</lpage>
          <pub-id pub-id-type="pmid">8504046</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lister</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Jolles</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Whittaker</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Forgacs</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cramp</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2000</year>
          <volume>43</volume>
          <fpage>403</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="pmid">10901735</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krastev</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Vassilev</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>GI amyloidosis treated with megadoses of i.v. gammaglobulin</article-title>
          <source>Hepatogastroenterology</source>
          <year>1994</year>
          <volume>41</volume>
          <fpage>204</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="pmid">8056416</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wittstock</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Benecke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zettl</surname>
              <given-names>UK</given-names>
            </name>
          </person-group>
          <article-title>Therapy with intravenous immunoglobulins: complications and side-effects</article-title>
          <source>Eur Neurol</source>
          <year>2003</year>
          <volume>50</volume>
          <fpage>172</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="pmid">14530624</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>(A) Joints are severely restricted in motion when fingers are fully extended. (B) Marked improvement in the range of motion three weeks after the 3rd hdIVIg therapy. (C) Biopsy from the lip shows pinkish amorphous homogeneous masses of amyloid in dermis, subcutaneous tissue, and muscle (Congo red stain; original magnification &#xD7; 40). (D) Congo red stain produces apple-green birefringence under a polarized light microscope (original magnification &#xD7; 40).</p>
      </caption>
      <graphic xlink:href="ymj-47-737-g001"/>
    </fig>
    <table-wrap id="T1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Estimated Range of Motion of the Joints under Passive Movement</p>
      </caption>
      <graphic xlink:href="ymj-47-737-i001"/>
      <table-wrap-foot>
        <fn>
          <p>Data are given in degrees unless otherwise indicated.</p>
          <p>MPJ, Metacarpophalangeal joint; PIP, Proximal interphalangeal joint; IP, Interphalangeal joint.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
